RTTNews | Nov 10, 2021 04:00AM EST

04:00 Wednesday, November 10, 2021 (RTTNews.com) - Evotec SE (EVO) has reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb (BMY) resulting in payments of $40 million to the company. The collaboration was started in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. The collaboration leverages Evotec's industrialised iPSC platform using patient-derived disease models.

Evotec said these target-based programme designations further bolster the growing pipeline and are expected to follow EVT8683, which Bristol Myers Squibb opted to license.

Read the original article on RTTNews ( https://www.rttnews.com/3241110/evotec-reaches-additional-programme-designations-within-collaboration-with-bristol-myers.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved